Live Feeds
● LIVE Updated 1h ago · 15 sources tracked

Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

Detailed phase 3 trial results confirm that the individualized mRNA cancer vaccine intismeran autogene, combined with pembrolizumab, significantly reduced the risk of melanoma recurrence or death compared to pembrolizumab alone. Six melanoma specialists affirmed the findings as a clinically meaningful advancement for patients treated after surgery. While the data surpassed analyst predictions, public sharing of preliminary metrics on social media previously triggered sharp stock volatility and a drop in Moderna shares due to valuation concerns. The therapy targets unique tumor neoantigens to prevent cancer return.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (15)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Intismeran autogene combined with KEYTRUDA reduced the risk of recurrence or death by 42% compared to KEYTRUDA alone for patients with completely resected stage IIB-IV melanoma.
  • ✓ A pre-specified sensitivity analysis showed that the combination reduced the risk of recurrence or death by 58% after six months following the intismeran immunization regimen.
  • ✓ Intismeran autogene is a novel investigational mRNA-based individualized neoantigen therapy built from each patient's own tumor.
🛡️ Source Corroboration: 15 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Full trial data were presented at the ESMO 2026 presidential symposium, confirming that the combination therapy met its primary endpoints.

Live updates

  1. Moderna-Merck Melanoma Vaccine Met Key Trial Endpoints

    Detailed phase 3 trial results confirm that the individualized mRNA cancer vaccine intismeran autogene, combined with pembrolizumab, significantly reduced the risk of melanoma recurrence or death compared to pembrolizumab alone. Six melanoma specialists affirmed the findings as a clinically meaningful advancement for patients treated after surgery. While the data surpassed analyst predictions, public sharing of preliminary metrics on social media previously triggered sharp stock volatility and a drop in Moderna shares due to valuation concerns. The therapy targets unique tumor neoantigens to prevent cancer return.

    Why it matters

    The Phase 3 INTerpath-001 trial evaluated the vaccine, also known as V940 or mRNA-4157, jointly developed by Merck and Moderna. Success in this trial could pave the way for similar mRNA-based treatments across other oncology indications. The therapeutic approach is designed for administration post-surgery rather than for primary prevention.

    What is confirmed

    • Intismeran autogene combined with KEYTRUDA reduced the risk of recurrence or death by 42% compared to KEYTRUDA alone for patients with completely resected stage IIB-IV melanoma.
    • A pre-specified sensitivity analysis showed that the combination reduced the risk of recurrence or death by 58% after six months following the intismeran immunization regimen.
    • Intismeran autogene is a novel investigational mRNA-based individualized neoantigen therapy built from each patient's own tumor.

    What to watch next

    • Further clinical developments and regulatory filings for intismeran autogene in additional cancer types beyond melanoma.
    Sources used for this update (15)
    1. cancer.aestheticsadvisor.com — Moderna and Merck’s Personalized mRNA Cancer Vaccine: Phase 3 ...
    2. WSJ — Moderna’s Shares Plummet After Cancer-Vaccine Data Shared on Social Media
    3. www.merck.com — Merck and Moderna Will Present Results From Landmark Phase 3 ...
    4. Yahoo Finance — Moderna stock crashes as leaked melanoma data threatens its record August rally
    5. STAT — Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
    6. Reuters — Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
    7. CNN — Experimental mRNA vaccine cuts risk melanoma returns by 42%
    8. The New York Times — Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Drug Makers Report
    9. AP News — A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
    10. BBC — World first personalised cancer vaccine stops disease returning in major trial
    11. www.statnews.com — Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
    12. www.cnbc.com — Moderna, Merck's cancer vaccine data a major advancement - CNBC
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community